Signal transduction pathways in sarcoma as targets for therapeutic intervention

被引:20
作者
Tuveson, DA
Fletcher, JA
机构
[1] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[2] MIT, Ctr Canc, Cambridge, MA 02139 USA
[3] MIT, Dept Biol, Cambridge, MA 02139 USA
[4] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA
[5] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[6] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA
[7] Harvard Univ, Sch Med, Boston, MA USA
关键词
D O I
10.1097/00001622-200107000-00007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Investigations into the molecular alterations in sarcomas have made substantial progress during the past decade. Classical linkage analysis and the direct sequencing of chromosomal translocation fusions have identified candidate genes in many different sarcomas, A large group of these genes participate in signal transduction pathways and represent potential sites of disease intervention with targeted therapies. This review will discuss five types of sarcoma that display aberrant tyrosine kinase pathway signaling: gastrointestinal stromal tumor, inflammatory myofibroblastic tumor, congenital fibrosarcoma and mesoblastic nephroma, dermatofibrosarcoma protuberans, and desmoplastic small round cell tumor; one sarcoma predisposition syndrome with specific dysregulation of the ras pathway-neurofibromatosis-will also be discussed. (C) 2001 Lippincott Williams & Wilkins, Inc.
引用
收藏
页码:249 / 255
页数:7
相关论文
共 84 条
  • [1] PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO
    ALESSI, DR
    CUENDA, A
    COHEN, P
    DUDLEY, DT
    SALTIEL, AR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) : 27489 - 27494
  • [2] BADER JL, 1986, ANN NY ACAD SCI, V486, P57
  • [3] THE NF1 LOCUS ENCODES A PROTEIN FUNCTIONALLY RELATED TO MAMMALIAN GAP AND YEAST IRA PROTEINS
    BALLESTER, R
    MARCHUK, D
    BOGUSKI, M
    SAULINO, A
    LETCHER, R
    WIGLER, M
    COLLINS, F
    [J]. CELL, 1990, 63 (04) : 851 - 859
  • [4] ABERRANT REGULATION OF RAS PROTEINS IN MALIGNANT-TUMOR CELLS FROM TYPE-1 NEUROFIBROMATOSIS PATIENTS
    BASU, TN
    GUTMANN, DH
    FLETCHER, JA
    GLOVER, TW
    COLLINS, FS
    DOWNWARD, J
    [J]. NATURE, 1992, 356 (6371) : 713 - 715
  • [5] Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells
    Bollag, G
    Clapp, DW
    Shih, S
    Adler, F
    Zhang, YY
    Thompson, P
    Lange, BJ
    Freedman, MH
    McCormick, F
    Jacks, T
    Shannon, K
    [J]. NATURE GENETICS, 1996, 12 (02) : 144 - 148
  • [6] Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors
    Bourgeois, JM
    Knezevich, SR
    Mathers, JA
    Sorensen, PHB
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2000, 24 (07) : 937 - 946
  • [7] Buchdunger E, 1996, CANCER RES, V56, P100
  • [8] Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139
  • [9] CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
    Carroll, M
    OhnoJones, S
    Tamura, S
    Buchdunger, E
    Zimmermann, J
    Lydon, NB
    Gilliland, DG
    Druker, BJ
    [J]. BLOOD, 1997, 90 (12) : 4947 - 4952
  • [10] A MAJOR SEGMENT OF THE NEUROFIBROMATOSIS TYPE-1 GENE - CDNA SEQUENCE, GENOMIC STRUCTURE, AND POINT MUTATIONS
    CAWTHON, RM
    WEISS, R
    XU, GF
    VISKOCHIL, D
    CULVER, M
    STEVENS, J
    ROBERTSON, M
    DUNN, D
    GESTELAND, R
    OCONNELL, P
    WHITE, R
    [J]. CELL, 1990, 62 (01) : 193 - 201